NHLBI funds preclinical tests on devices for infants and children with congenital hea... (studies and other tests in artificial en...)

NHLBI funds preclinical tests on devices for infants and children with congenital heart defects

Date:2/4/2010

studies and other tests in artificial environments for the most promising devices in order to gain approval from the FDA to begin clinical testing.

Devices in the program will provide suitable circulatory support for newborns, older infants, and children less than 55 pounds who experience heart failure due to congenital and acquired cardiovascular disease. They are designed to supply adequate blood flow to prevent organ damage while minimizing the risk of blood vessel damage, infection, breakdown of red blood cells, excessive bleeding, brain damage, and dangerous blood clots. The devices are intended to support circulation in pediatric patients for one to six months, be sufficiently small and reasonably portable, and be able to be routinely positioned and functioning in less than one hour, among other specifications.

"Similar devices are used in adults," Shurin noted. "As an adult, your heart is normally about the size of your fist; devices for small children require radically different designs from adult devices to adapt to the differences in the size of the patients."

The program will test ventricular assist devices (VADs) and advanced extracorporeal membrane oxygenator (ECMO) devices. The VADs in the PumpKIN program are very small rotary pumps which are implanted to provide circulatory support for extended periods of use. They work by drawing blood from the heart and pumping it to the body. ECMO devices circulate and supply oxygen to the blood, and are commonly used for patients who need both heart and lung support. For ECMO devices, tubes connecting the patient to the device are placed directly into large blood vessels near the base of the neck. Blood is drawn from the right side of the heart, pumped through the oxygenator, and then returned to the body on the left side of the heart so the oxygen-rich blood can be delivered throughout the body.

The contractors will conduct all preclinical animal testing and analysis i
'/>"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
2. Porter Novelli Begins Work With NHLBI on COPD Awareness Effort
3. NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
4. Highlights of NHLBI-supported research presented at American Heart Associations Scientific Sessions
5. Pitt part of $100 million NHLBI Bench to Bassinet effort in congenital heart disease
6. NHLBI publishes new heart healthy cookbook
7. BlueCare(R) Family Plan, a HUSKY Health Plan from Anthem Blue Cross and Blue Shield in Connecticut, Raises Awareness, Funds and Diapers for New Haven Diaper Bank
8. Canadas government funds $1.6M in modern geography to support public health decisions
9. Computerized Jump Rope Raises Funds for Breast Cancer Research
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. New Study Finds Medicaid Under-Funds Long Term Care by $4.4 Billion Annually

Post Your Comments:

(Date:5/23/2013)... Jim Fitzpatrick just did it again. ... yet another outside-of-the-box approach to reaching the retail automotive ... daily newscasts to the retail automotive industry, blending the ... broadcast news format. , CBTNews.com is an innovative ... Bridget Everett and Russell Brown host the show with ...

(Date:5/23/2013)... (PRWEB) May 23, 2013 NDI ... funds and develops innovative neurodevice technologies, has launched ... (DBI). DBI will commercialize its groundbreaking technology ... (DBS) therapy for patients with Parkinson’s disease. ... Parkinson’s disease and generates more than $275 million ...

(Date:5/23/2013)... The Viewpoints with Terry Bradshaw show ... a dim life after work ends. A Pew Charitable Trust ... 1955 -- carry more debt, have higher mortgages and are ... Golden Years is not lost. The program brings information to ... after reaching the retirement age of 67, while still enjoying ...

(Date:5/23/2013)... scientifically known about the human potential to cultivate compassion ... are suffering in a way that motivates altruistic behavior. ... Center for Investigating Healthy Minds at the Waisman Center ... be trained to be more compassionate. The report, recently ... is the first to investigate whether training adults in ...

(Date:5/23/2013)... an important human pathogen that can cause rapidly progressing, ... Jennings said., "Until now we have not known how ... a long-standing mystery how it attaches to the airway ... and not get any symptoms, while some people progress ... to know the detail of how the bacterium colonises ...

Breaking Medicine News(10 mins):Health News:Fitzpatrick Advertising Founder Brings Auto Industry into Focus with CBT News 2 Health News:NDI Launches Deep Brain Innovations, LLC 2 Health News:NDI Launches Deep Brain Innovations, LLC 3 Health News:Viewpoints with Terry Bradshaw Presents a Series on Redefining Retirement 2 Health News:Study shows people can be trained to be more compassionate 2 Health News:Study shows people can be trained to be more compassionate 3 Health News:Study shows people can be trained to be more compassionate 4 Health News:New discovery in fight against deadly meningococcal disease 2

[0] Fitzpatrick Advertising Founder Brings Auto Industry into Focus with CBT News [0] NDI Launches Deep Brain Innovations, LLC [0] Viewpoints with Terry Bradshaw Presents a Series on Redefining Retirement [0] Study shows people can be trained to be more compassionate [0] New discovery in fight against deadly meningococcal disease

... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... corporate activities, including (1) the receipt of a Phase ... National Institutes of Health ("NIH"), (2) a presentation by ... Public Health on the significant advantages in throughput ...

... Positive Committee Recommendation in European UnionCorporate Highlights:- ... Qutenza(TM) (formerly NGX-4010) for treatment of peripheral ... or in combination with other medicinal products ... by U.S. FDA for PHNUpcoming 2009 Milestones:- ...

... to Spot Punctures SoonerNORCROSS, Ga., March 20 Molnlycke ... and the only major surgical glove company with an ... its line this month that helps clinicians notice punctures ... two polyisoprene surgical gloves already in the line. ...

... 20 JLL Partners, a leading private equity investment ... provider of clinical development services (Nasdaq: PDGI ... tender offer by JLL PharmaNet Holdings, LLC ("Parent"), through ... of the outstanding shares of common stock of PharmaNet. ...

... an across-the-board increase in Californai Medicare supplement insurance plan premiums ... for new ways to maximize healthcare dollars and minimize expenses. ... ... March 20, 2009 -- Anthem Blue Cross implemented an across-the-board ...

... indicates that some aspects of peoples, cognitive skills such ... and detect relationships peak at about the age of ... 27. , "This research suggests that some aspects of age-related ... in their 20s and 30s," said Timothy Salthouse, a University ...

Pressure BioSciences, Inc. Provides Corporate Update NeurogesX Reports Fourth Quarter and Year-End 2008 Results Biogel Introduces Polyisoprene (PI) Indicator Underglove JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period Seniors Seek to Reduce Healthcare Costs as Anthem Blue Cross Increases Premiums Cognitive decline begins in late 20s, study suggests

(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...

(Date:5/23/2013)... BOSTON , May 23, 2013 PAREXEL International ... it will be presenting at the Jefferies Healthcare Conference ... Vice President and Chief Financial Officer, will be ... at 1:30 p.m. ET on Monday, June 3, 2013. ... available through the "Investors" section of PAREXEL,s website at ...

(Date:5/23/2013)... Mai 2013 Ranbaxy Laboratories ... von Daiichi Sankyo Co., Ltd. (im ... Mai die Maßnahmen bekannt, die Ranbaxy ... um sich der Angelegenheiten der vorhergehenden ... ). Daiichi Sankyo unterstützt ...

Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3 PAREXEL International To Present At Jefferies Healthcare Conference 2 Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2

[0] Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition [0] PAREXEL International To Present At Jefferies Healthcare Conference [0] Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an

... March 23 Magellan Biosciences, Inc., an emerging ... has become the first to offer minocycline and telavancin ... and Drug Administration (FDA) has cleared TREK-brand Sensititre MIC ... negative bacterial isolates, as well as telavancin against Gram ...

... and MORRISTOWN, N.J. , March 23 MicroMass Communications, Inc., a world leader in behavioral marketing, ... be supporting the launch of the new center and its mission of promoting the growth of North Carolina ,s ... ... , , ...

Cached Medicine Technology:FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 2 FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 3 FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 4 MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 2 MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 3 MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 4

FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Homocystine, Urine Quantitative HNPCC HLA-B27 by PCR & Fluorescence Monitoring HLA-A & B Phenotype